Inspired Capital plc

I was unfortunately and publicly proved right about two events last week. Unfortunate, because neither was a positive outcome. On the Brexit vote, I was right partly for the wrong reason since I guess

If recent investments in Series A funding rounds are any indication, the troubled early-stage segment of biotechnology venture capital fundraising is headed for a year-end rebound. In the days leading

Phytopharm's Cogane has comprehensively failed the Phase II CONFIDENT-PD trial for the treatment of early stage Parkinson's disease patients. Cogane had no beneficial effects on patients' symptoms mea

As companies flurried to clinch deals by the end of the year, a number of significant agreements were signed or completed last December. Notable among them were Amgen's $415 million deal to buy Icelan